Search - tctmd.com

Displaying 161 - 180 of 267

Sort: Relevancy | Date

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI

Michael O'Riordan

June 10, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

AI-ECG Allows for Early Diagnosis of Low EF

Yael L. Maxwell

May 10, 2021

News Conference News SCAI 2021

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

Michael O'Riordan

May 06, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Pneumonia in HF Patients Is Common, Lethal, and Preventable

L.A. McKeown

April 19, 2021

News Features

AI in Cardiology: Where We Are Now and Where to Go Next

Yael L. Maxwell

March 30, 2021

News Daily News

No Gravity, Smaller Hearts: LV Mass Declines in Space and Water

Michael O'Riordan

March 29, 2021

News Daily News

Patient-Reported Outcomes Beat NYHA Class for Tracking Gains in HFrEF

L.A. McKeown

March 25, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2021

Shelley Wood

March 02, 2021

News Opinion CV Team Dispatch

March 2021 News Roundup

L.A. McKeown

March 01, 2021

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

L.A. McKeown

February 04, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

L.A. McKeown

February 01, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

L.A. McKeown

January 11, 2021

Advertisement

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI

June 2021 News Roundup

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

AI-ECG Allows for Early Diagnosis of Low EF

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

FDA Approves Dapagliflozin for CKD Patients

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Pneumonia in HF Patients Is Common, Lethal, and Preventable

AI in Cardiology: Where We Are Now and Where to Go Next

No Gravity, Smaller Hearts: LV Mass Declines in Space and Water

Patient-Reported Outcomes Beat NYHA Class for Tracking Gains in HFrEF

TCTMD’s Top 10 Most Popular Stories for February 2021

March 2021 News Roundup

Did Regional Differences Muddy Results in COMMANDER-HF?

February 2021 News Roundup

FDA Approves Vericiguat for High-risk Patients With HF

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content